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Synopsis
Pancreatic cancer stem-like cells are described by membrane expression of CD24, CD44 and ESA (epithelial-speciﬁc
antigen) and their capacity to grow as spheres in a serum-free medium containing well-deﬁned growth factors. The
capacity of a panel of four pancreatic cancer cell lines (PANC-1, CFPAC-1, PancTu-1 and PSN-1) to form spheres
was tested. All cell lines with the exception of PancTu-1 developed spheres. Phenotypically, the sphere-growing cells
showed an increased in vitro invasion capability. Both gene and protein expressions of markers of metastases
[CXCR4 (CXC chemokine receptor 4), OPN (osteopontin) and CD44v6] and components of active hedgehog pathway
signalling were assessed. Spheres clearly demonstrated increased expression of the above-mentioned markers when
compared with their adherent counterpart. With the aim of identifying a minimum set of markers able to separate
cells that have the capacity to form spheres from those incapable of forming spheres, a PCA (principal component
analysis) of the multidimensional dataset was performed. Although PCA of the ‘accepted’ stemness genes was
unable to separate sphere-forming from sphere-incapable cell lines, the addition of the ‘aggressiveness’ marker
CD44v6 allowed a clear differentiation. Moreover, inoculation of the spheres and the adherent cells in vivo conﬁrmed
the superior aggressiveness (proliferation and metastasis) of the spheres over the adherent cells. In conclusion, the
present study suggests that the sphere-growing cell population is not only composed of cells displaying classical stem
membrane markers but also needs CD44v6-positive cells to successfully form spheres. Our results also emphasize
the potential therapeutic importance of pathways such as CXCR4 and hedgehog for pancreatic cancer treatment.
Key words: adherently growing cell, cancer marker, pancreatic cancer, principal component analysis (PCA),
sphere-growing cell
INTRODUCTION
Pancreaticcancerisoneofthemostlethalhumancancerswithan
overall5-year survivalrateof3–5% andamediansurvivalofless
than6months.Theveryshortsurvivalratesmaybeduetothefact
that there are no appropriate diagnostic tools for early detection.
Metastatic seeding is one of the major features of pancreatic
cancer (occurring in more than 80% of cases), and metastases
to loco-regional lymph nodes or liver are often already present
at the time of diagnosis. Despite the efforts made in the past
50 years, conventional treatment approaches have little impact
on the course of this aggressive neoplasm [1].
............................................................................................................................................................................................................................................................................................................
Abbreviations used: AML, acute myelogenous leukaemia; CSM, cancer stem cell medium; CK-19, serum cytokeratin 19; CXCR4, CXC chemokine receptor 4; DM, differentiation
medium; DMEM, Dulbecco’s modiﬁed Eagle’s medium; DPBS, Dulbecco’s PBS; EGF, epidermal growth factor; ESA, epithelial-speciﬁc antigen; FBS, fetal bovine serum; FGF, ﬁbroblast
growth factor; GEM, gemcitabine; Gli, glioma-associated oncogene homologue; HGF, hepatocyte growth factor; H/E, haematoxylin/eosin; Isl-1, insulin gene enhancer protein 1; MRI,
magnetic resonance imaging; OPN, osteopontin; PCA, principal component analysis; PDX-1, pancreatic and duodenal homeobox-1; Ptch, patched homologue; QRT-PCR, quantitative
real-time PCR; RPLP0, ribosomal protein, large, P0; SDF-1, stromal-derived factor-1α; Shh, sonic hedgehog
1To whom correspondence should be addressed (email margherita.gaviraghi@tiscali.it).
Since 1997, the U.S. FDA (Food and Drug Administration)
approved GEM (gemcitabine) for ﬁrst-line treatment of patients
with locally advanced or metastatic adenocarcinoma of the pan-
creas. This approval was based on a slight clinical beneﬁt re-
sponse and survival for GEM versus 5-ﬂuorouracil observed in a
relativelysmallrandomizedphaseIIIstudyincluding126patients
[2]. Despite the introduction of GEM in the current therapeutic
treatment as a single agent, the effectiveness of chemotherapy
still remains limited and highly inefﬁcient [3]. A potential ex-
planation for the failure of the classical therapeutic approaches
for pancreatic cancer might be because the agents only target the
proliferating cells [4]. In the last few years, it has been extens-
ively demonstrated that tumours are composed of different cell
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populations,ofwhichasmallsubsetdisplaysstemcellproperties
(e.g. high plasticity, multipotentiality, capacity to grow at clonal
density and higher capacity to migrate) [5].
Cancer stem cells (also called cancer progenitor cells, cancer
stem-like cells etc.), ﬁrst identiﬁed in a subset of AML (acute
myelogenous leukaemia) cells, were shown to be similar to nor-
mal haemopoietic stem cells and to be able to induce AML in
immunodeﬁcientmice[6].Subsequently,thepresenceofahighly
aggressive and potentially chemoresistant cancer stem cell pop-
ulation was demonstrated in a large panel of solid tumours.
As for other solid tumours, pancreatic cancers were demon-
strated to contain cancer stem cells. Li et al. [7] reported that
CD44+CD24+ESA+ (where ESA is epithelial-speciﬁc antigen)
cells possess characteristics and properties of stem cells, as they
showed a 100-fold increased tumorigenic potential compared
with the triple negative population when xenografted in immun-
odeﬁcient mice.
Also, Hermann et al. [8] demonstrated that pancreatic cancers
contain different subpopulations of cells. They deﬁned a distinct
subset of CD133+/CXCR4+ cells {CXCR4 (CXC chemokine
receptor 4) is the receptor for the chemokine CXCl12 [also
known as SDF-1 (stromal-derived factor-1α)]} that localizes to
the invasive edge of primary pancreatic carcinomas. This cell
population exhibited a signiﬁcantly stronger migratory activity
in vitro and was revealed to be more metastatic in vivo than
CD133+/CXCR4− cells. Kolb et al. [9] correlated the increased
OPN(osteopontin)expressioninpancreaticcelllinesandtumour
specimens with increased metastatic seeding.
Recently, Jimeno et al. [10] discovered in a pancreatic can-
cer xenograft that GEM treatment resulted in an enrichment of
pancreaticcancerstemcells(CD24+ andCD44+),whichpromp-
ted the repopulation of the proliferating cells after GEM release.
OnlythecombinedtreatmentofGEMwiththehedgehogpathway
inhibitor cyclopamine resulted in signiﬁcant tumour shrinkage.
Moreover, the hedgehog inhibitor was able to reduce both static
and dynamic markers of cancer stem cells.
The results of our present study, in which we have demon-
strated that stemness markers are not sufﬁcient to completely de-
scribe sphere-growing cells, conﬁrm the hypothesis that sphere-
growing cells not only display stem cell characteristics but can
also be considered as the aggressive subpopulation of pancreatic
tumours. Based on our ﬁndings, we were able to generate a test
system that can readily be applied to the identiﬁcation of poten-
tial drug targets which are speciﬁc to the pancreatic cancer stem
cell niche.
MATERIALS AND METHODS
Cell lines and culture conditions
Human pancreatic cancer cell lines PANC-1, PSN-1, CFPAC-1
and PancTu-1 cells (A.T.C.C.) were grown in RPMI 1640 (Cam-
brex Bioscience, Milan, Italy) supplemented with 10% (v/v)
FBS (fetal bovine serum; Cambrex Bioscience, Milan, Italy),
100 units/ml penicillin and 0.1 mg/ml streptomycin. Adherent
cells were maintained in standard conditions for a few passages
at 37◦C with 5% CO2 and detached using trypsin/EDTA solu-
tion (trypsin 0.25% and EDTA 0.02%). Cells were routinely
checked for mycoplasma contamination using a PCR-based
method [11].
To generate suspension cells and separate stem-like sphere-
growing cells, adherent cells were washed twice in Dulbeccos
PBS 1× (Cambrex Bioscience, Milan, Italy) and then cultured in
DMEM (Dulbecco’s modiﬁed Eagle’s medium)+F-12 (1:1) sup-
plemented with 1×B27 (Gibco, Invitrogen), 1 pg/ml Fungizone,
1% penicillin/streptomycin (Gibco, Invitrogen), 5 μg/ml heparin
(Sigma)and20 ng/mlEGF(epidermalgrowthfactor)/FGF(ﬁbro-
blast growth factor; Peprotech). The medium is referred to as
CSM (cancer stem cell medium). Adherent cells were left in
CSM for at least 3–4 weeks or until the appearance of ﬂoating
cell aggregates, referred to as pancreatic cancer spheres. Spheres
were collected without disturbing the adherent cells and sub-
cultured in CSM for at least four passages before initiating the
characterization experiments.
Drugs and chemicals
GEM (Gemzar, Lilly) stocks (40 mg/ml solution) were stored in
aliquots at –20◦C and single aliquots were utilized for the drug
treatment.
QRT-PCR (quantitative real-time PCR)
Total RNA was isolated from PANC-1 spheres and PANC-1,
PSN-1, CFPAC-1 and PancTu-1 adherent cell lines using the
RNeasy Mini kit (Qiagen, Hilden, Germany) according to the
standard protocol provided by the manufacturer, with on-column
DNA digestion. RNA integrity and concentration was analysed
using Agilent Technology and 1 μg of RNA was retrotranscribed
intocDNAusingtheFirstStrandcDNASynthesiskitfromRoche
(Mannheim, Germany). SYBR-Green Technology (Applied
Biosystems) was used for all QRT-PCR experiments. A 20 μl
portion of the PCR reaction mixture containing 6 μl of template
cDNA (diluted 1:25), 10 μl of SYBR-Green reagent and 0.5
μmol/l of speciﬁc primers was used for each QRT-PCR reaction.
The primers used were: 5 -ACATGTTGCTGGCCAATAA-
GGT-3  and 5 -CCTAAAGCCTGGAAAAAGGAGG-3  for
RPLP0 (ribosomal protein, large, P0), 5 -GCATTGGCATC-
TTCTATGGTT-3  and5 -CGCCTTGTCCTTGGTAGTGT-3  for
CD133, 5 -TCCAACTAATGCCACCACCAA-3  and 5 -GA-
CCACGAAGAGACTGGCTGT-3  for CD24, 5 -CCGCTGC-
GAGGACGTAGA-3  and 5 -TGTTGGCTGCGTCTCATCAA-
AACC-3  for ESA, 5 -AGAAGGTGTGGGCAGAAGAA-3  and
5 -AAATGCACCATTTCCTGAGA-3  for CD44, 5 -AGGAA-
CAGTGGTTTGGCAAC-3  and 5 -CGAATGGGAGTCTTCT-
CTGG-3  for CD44v6, 5 -AGGGAGGAAAGCAGACTGAC-3 
and 5 -CCAGTCATTTCCACACCACT-3  for Gli-1 (glioma-
associated oncogene homologue 1), 5 -CGCCTATGCC-
TGTCTAACCATGC-3  and 5 -AAATGGCAAAACCTGA-
GTTG-3  for Ptch (patched homologue), 5 -CAAAAAGGAA-
ACGCAAAGACG-3  and 5 -AGCAAATCACTGCAATTC-
TCA-3  for OPN, 5 -GGACAGGCTGATGACTCAGA-3  and
..........................................................................................................................................................................................................................................................................................................................................................................
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5 -CAAAAGGAAACGCAAAGACG-3  for Shh (sonic hedge-
hog). Thermal cycle protocols were performed for 40 cycles
of 10 s at 95◦C, 30 s at 60◦C. All PCR reactions were carried
out using the ABI Prism 7000 instrument (Applied Biosystems)
and analysed by ABI Prism 7000 SDS software. To conﬁrm
ampliﬁcation speciﬁcity, PCR products were subjected to a
melting curve analysis. In order to avoid potential interference
of the cell culture conditions with the expression of typically
used cytoskeletal markers, the ribosomal protein RPLP0 was
selected and validated as the most reliable housekeeping gene.
QRT-PCR average values of PANC-1, PSN-1, CFPAC-1 and
PancTu-1adherentcellscalculatedforthetenselectedgeneswere
normalizedbydividingeachcelllinedatasetbyitsstandarddevi-
ation. PCA (principal component analysis) was performed with
Matlab Statistics Toolbox (The MatWorksTM) and visualization
of the PCA shows the principal components.
FACS
PANC-1 adherent cells were grown up to 70% conﬂuency. The
adherentcellsweretrypsinizedfordissociation,whilethespheres
were mechanically dissociated avoiding all potentially sphere
compromising manipulations. Subsequently, both cell suspen-
sions were washed twice with Hanks balanced salt solution
(Gibco, Invitrogen) containing 2% FBS (FACS buffer) and re-
suspended in FACS buffer at a density of 100000 cells/100 μl.
Direct-labelled antibodies, anti-CD44-allophycocyanin, anti-
CD24-phycoerythrin (BD Bioscience, Pharmingen), ESA–FITC
(BD Immunocytometry Systems) and PECXCR4 (BD Bios-
cience, Pharmingen) used at a dilution of 1:40, were incubated
for 20 min on ice. For the analysis of CD44v6, cells were resus-
pendedinFACSbufferatadensityof200000cells/50 μl.Direct-
labelled antibodies anti-CD44v6 allophycocyanin and Mouse
IgG1 Isotype Control-APC (R&D Systems) were used at a di-
lution of 1:2.5, and incubated for 45 min on ice. Subsequently,
each sample was washed twice with FACS buffer and samples
were analysed employing a FACSAria instrument (BD Immuno-
cytometry Systems).
Differentiation proﬁle of pancreatic cancer stem
cells
Toevaluatethedifferentiationpatternofspheres,thesphereswere
dissociated into single cells and plated on to Permanox chamber
slides(Lab-Tek,Nunc)atadensityof100cellsperwell.PANC-1
adherent cells were cultured in RPMI 1640 containing 10% FBS
and1%penicillin/streptomycinfor10 days.Tofavourcellattach-
mentanddifferentiationofPANC-1spheres,cellswereincubated
for 10 days at 37◦C in CSM without EGF/FGF but with the ad-
dition of 1% FBS [referred to as DM (differentiation medium)].
After the differentiation induction, the expression of progenitor
and differentiation markers [PDX-1 (pancreatic and duodenal
homeobox-1), Isl-1 (insulin gene enhancer protein 1) and CK-
19 (serum cytokeratin 19)] in PANC-1 spheres was compared
with that in adherent PANC-1 cells using immunocytochemistry.
Approx. 10 million PANC-1 spheres were ﬁxed for 10 min in
4% (w/v) paraformaldehyde, resuspended in a warm solution of
1% agar dissolved in PBS and transferred to a bottom cut Ep-
pendorf tube until complete agar solidiﬁcation. Cells embedded
in solidiﬁed agar were then embedded in parafﬁn, cut into sec-
tions and further processed and analysed for immunocytochem-
istry. (The protocol is available at http://icg.cpmc.columbia.edu/
cattoretti/Protocol/immunohistochemistry/Cell_block.html.)
The adherent cells were ﬁxed for 10 min with 4% paraform-
aldehyde, brieﬂy washed with PBS and incubated for 15 min
in PBS containing 1% BSA for speciﬁc antibody blocking.
Cells were subsequently incubated overnight with anti-PDX-
1, anti-Isl-1 (both from Abcam) and anti-CK-19 (clone BA17,
Dako) at dilutions of 1:5500, 1 μg/ml and 1:100 respectively. For
CK-19,antigenretrievalwasperformedfor5 minincitratebuffer
(10mM citric acid and 0.05% Tween 20, pH 6) at 99◦C. All im-
munocytochemical reactions were developed using a NovoLinK
Polymer Detection System kit (Visionbiosystems, Novocastra).
All images were acquired using a DMD108 microscope (Leica
Microsystems). The positivity of the antibody staining was quan-
tiﬁed by counting the number of positive cells versus the total
number of cells (minimum 500 cells were counted per condition)
in both growth conditions.
Transwell migration assay
In vitro chemotaxis was assayed using the HTS Transwell-96
system from Corning (Corning, NY, U.S.A.). Cells were starved
overnight in a serum-free medium with and without SDF-1
(100 ng/ml). A 100 μl portion of cells diluted at 75×104/ml in
migration buffer (DMEM with 5% BSA) was placed in the upper
wells, whereas the chemoattractants [HGF (hepatocyte growth
factor), SDF-1, FBS and CSM] diluted in a serum-free medium
were added to the lower wells. Polyester membranes with a pore
size of 1.3 μm were used and incubation was performed at 37◦C
in a 5% CO2 atmosphere for 48 h. At the end of the reaction,
migrated cells were detached by placing transwell chambers for
15 min on ice, stained with CyQuant dye and counted using a
ﬂuorescence plate reader (M1000 Inﬁnite®; Tecan). All experi-
ments were performed in triplicate.
Subcutaneous xenografts generated from adherent
and sphere-growing pancreatic cancer cells
All animal experiments were carried out according to the eth-
ical standards of the Verona University Review Board, and the
animals were maintained in accordance with the institutional
guidelines. A total of 2×106 adherent and sphere-growing pan-
creatic cancer cells in a ﬁnal volume of 100 μl were injected into
therightﬂankoffemaleathymicCD1mice(4-week-old,Charles
River). Typically, cells were resuspended in a total volume of
100 μl of DPBS and injected subcutaneously. Tumour develop-
ment was monitored for 30 days. At the end of the study, an-
imals were killed and tumour samples were formalin-ﬁxed,
embedded in parafﬁn, sectioned, deparafﬁnized using xylene
and hydrated by a series of decreasing ethanol washes. H/E
(haematoxylin/eosin) and Ki67 immunohistochemical staining
..........................................................................................................................................................................................................................................................................................................................................................................
www.bioscirep.org / Volume 31 (1) / Pages 45–55 47M. Gaviraghi and others
was performed. Ki67 (clone MM1; Novocastra) was diluted 1:50
and antigen retrieval was performed at 95◦C for 15 min in pH 6
citrate buffer.
Generation of orthotopic human pancreatic cancer
xenografts in immunodeﬁcient mice
All animal experiments were carried out according to the eth-
ical standards of the Verona University Review Board, and the
animals were maintained in accordance with the institutional
guidelines.Atotalof5×105 adherentorsphere-growingPANC-
1 cells in a total volume of 30 μl of sterile PBS were injected
into the pancreas of ten female athymic CD1 mice (4 weeks old,
CharlesRiver):ﬁvereceivedspherescellsandﬁveadherentcells.
Animals were anaesthetized using ketamine/xylazine cocktail at
a ratio of 100 mg/kg:20 mg/kg and the mice were placed under a
heat lamp.
MRI (magnetic resonance imaging)
Mice were anaesthetized by inhalation of a mixture of air and
O2 containing 0.5–1% isoﬂuorane and placed into a 3.5 cm in-
ternal diameter transmitter–receiver birdcage coil. Images were
acquired using a Biospec Tomograph (Bruker, Karlsruhe, Ger-
many) equipped with a 4.7 T, 33-cm bore horizontal magnet
(Oxford Ltd, Oxford, U.K.). The respiration rate was monitored.
The imaging planes were both coronal and transverse.
RESULTS
Not all pancreatic cancer cell lines can form
spheres
Inordertotestwhetherpancreaticadherentcellslineswereableto
form spheres, a panel of four established cells lines was selected:
PANC-1, PSN-1 and PancTu-1 (derived from primary tumours)
and CFPAC-1 (derived from liver metastasis) [12]. Cell lines
were ﬁrst cultured as adherent cells for several passages, washed
with DPBS and subsequently cultured in CSM. Cells started to
lose their characteristic epithelial morphology within 24–36 h
after the incubation with CSM. They typically lost a rhomboidal
epithelial shape and became ﬂoating cells or cell clusters. After
1 week, the ﬂoating spheroids were collected without disturbing
the remaining adherent cells and grown until they reached a suf-
ﬁcient density to be transferred to a 75 cm ﬂask. After 4 weeks
a clear distinction between the cell lines that had the capabil-
ity to form spheres and the ones that had not could be made.
Three cell lines, PANC-1, PSN-1 and CFPAC-1, were capable
of forming spheres. They already demonstrated a signiﬁcant pro-
duction of ﬂoating cells 5 days after the addition of CSM and
a sufﬁcient number of spheres for subsequent experiments were
obtained after 3–4 weeks. Although there was a clear difference
inmorphologybetweenthespheresfromPANC-1,CFPAC-1and
PSN-1, they all demonstrated the capacity to grow in suspension
and to proliferate under CSM culture conditions for a long time.
PancTu-1 cells did not have the capacity to produce spheres
whenculturedinCSM.Mostofthecellsmaintainedtheircapacity
to adhere even in the presence of CSM, and only very few single
ﬂoatingcellswereformed.Also,separatingtheﬂoatingcellsfrom
theiradherentcounterpartsandreplatingtheminCSMconditions
did not result in the formation of spheres.
CD24, CD44 and ESA expression cannot
successfully separate sphere- from
non-sphere-forming pancreatic cancer cell lines
In order to further characterize the four pancreatic cell lines,
the expression of the reported cancer stem-like markers CD24,
CD44,ESAandCD133,aswellastheexpressionofthehedgehog
markersGli-1,Gli-2andSmoandofthe‘aggressiveness’markers
CXCR4, OPN and CD44v6, was quantiﬁed in all cell lines by
QRT-PCR. The obtained values were analysed using multivariate
statistical analysis, a quantitative method allowing interpretation
of high-dimensional datasets. In order to be able to generate a
minimum gene set necessary to distinguish those cell lines that
have the capacity to form spheres from the ones that do not, a
PCA was performed on the normalized data [13].
Using the pancreatic cancer stem-like markers CD24, CD44,
ESA and CD133, it was not possible to distinguish the ‘sphere-
capable’ from the ‘sphere-incapable’ cell lines. In fact, PancTu-1
resides in the same quadrant as the ‘sphere-capable’ cell lines
PANC-1andPSN-1(Figure1A).Inasubsequentexperiment,the
same PCA was carried out including CD44v6, a protein marker
of metastasis in pancreatic cancer. As shown in Figure 1(B), the
PCA now successfully separated the ‘sphere-capable’ from the
‘sphere-incapable’celllines.CFPAC-1islocatedintheﬁrstquad-
rant together with PSN-1 and PANC-1, and the sphere-incapable
PancTu-1 is clearly separated from the others. Moreover, the fact
that PANC-1 and PSN-1 reside closer to the axes origin may
reﬂect the difference in the capability of the cell lines to form
spheres. CFPAC-1 spheres have a different morphology as com-
pared with PANC-1 and PSN-1 spheres: CFPAC-1 spheres form
rounded, regular and melted spheres, which made them difﬁcult
to dissociate into single cells; PANC-1 and PSN-1 form very
similar spheres. PancTu-1 cells were unable to formspheres even
when they were cultured in CSM for more than 4 weeks. These
cells are well separated in the fourth quadrant from the three
others.
This analysis suggests that the earlier described stem cell
markers alone are not sufﬁcient to predict sphere formation
and that CD44v6 is essential to successfully predict the sphere-
forming capability of pancreatic cancer cell lines. Moreover,
FACS analysis demonstrated an increased membrane expres-
sion of CD44v6 protein in PANC-1 spheres compared with their
adherent counterpart. In a next step, a full characterization of
sphere-forming cells was performed.
Pancreatic cancer spheres demonstrate increased
expression of stem cell markers
PANC-1 cells were grown in two different medium conditions:
theadherentstandardcellcondition(RPMI1640+10%FBS)and
..........................................................................................................................................................................................................................................................................................................................................................................
48 C  The Authors Journal compilation C  2011 Biochemical SocietyStemness and invasiveness markers deﬁne pancreatic cancer spheres
Figure 1 PCA of CD44, ESA, CD24 and CD133 carried out in the absence and in the presence of CD44v6
(A) Cell line projection using stemness markers on the two ﬁrst principal components; the second principal component
clearly separates CFPAC from the others (PANC-1, PancTu-1 and PSN-1). The ﬁrst principal component does not distinguish
cells able to form spheres from those that do not. (B) Cell line projection of the stemness markers including CD44v6 on
the two ﬁrst principal components clearly shows three clusters, in agreement with the biological ability to form spheres.
Note: In this graphical representation, PANC-1 and PSN-1 are superimposed due to their vicinity.
CSM condition. The quantitative gene expression of the com-
plete panel of stem cell markers (CD24, CD44, ESA and CD133)
and of the metastatic marker CD44v6 was assessed in PANC-1
spheres and adherent cells. CD24 gene expression in
PANC-1spheresis25-foldgreaterthaninadherentcells(+ −2).Al-
thoughbothCD44s(CD44andCD44v6)andESAdidnotchange
signiﬁcantlytheirexpressionbetweenspheresandadherentcells,
theCD44v6ligandOPNdemonstrateda350(+ −30,P>0.01)fold
increased mRNA in spheres versus adherent cells. Also at the
protein level, increased positivity of the membrane marker CD24
was most striking in spheres versus adherent cells (Figure 2). In-
deed, FACS analysis revealed the presence of a restricted CD24+
subpopulation (8.5%) in adherent cells, whereas an enrichment
of positive cells was observed (32%) in spheres (Figures 2A
and 2B). Likewise, a signiﬁcant increase in triple positive cells
(CD24+,C D 4 4 + and ESA+) was observed in PANC-1 spheres
(21%) compared with adherent cells (7.9%; Figures 2C and 2D).
However, neither CD44 nor ESA expression levels varied signi-
ﬁcantly between adherent cells and spheres. Although there was
variability in CD133 expression in sphere-growing cells, their
expression was always signiﬁcantly greater than in adherent cells
in which no CD133 could be detected (results not shown). These
data are in agreement with an earlier study in which Olempska
et al. [14] demonstrated that PANC-1 adherent cells did not ex-
press CD133.
Pancreatic cancer spheres demonstrate typical
stem cell functionalities
In order to investigate whether PANC-1 sphere-growing cells
also display typical stem cell properties such as self-renewal and
multipotentiality, these features were evaluated.
Self-renewal, deﬁned as the ability of cells to go through
numerous cycles of cell division while maintaining the undiffer-
entiated state, was assessed by the spheres’ capacity to produce
second generation spheres. Cells were dissociated into single
..........................................................................................................................................................................................................................................................................................................................................................................
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Figure 2 Cell surface expression analysis of stemness markers in adherent and sphere-growing PANC-1 cells
(A) PANC-1 adherent CD24+,( B) PANC-1 spheres CD24+,( C) PANC-1 adherent CD24+CD44+ESA+ and (D) PANC-1 spheres
CD24+CD44+ESA+.
cells and plated on a 96-well plate as single cells per well. After
7–10 days, only 16% of the single cells were able to produce
second generation spheres and the newly formed spheres were
morphologically more regular than the initial spheres. These
observations conﬁrm that PANC-1 spheres represent a hetero-
geneous cell population that contains a stem-enriched subpopu-
lationofcells,potentiallyresponsibleformoreaggressivetumour
behaviour.
Multipotentiality, deﬁned as the capacity of progenitor cells
to differentiate into cells from a limited number of lineages,
was investigated by subjecting PANC-1 spheres to differenti-
ating conditions. Typically, dissociated spheres were grown in
differentiating conditions. After 10 days in DM, the cells com-
pletely attached to the plastic slides and acquired mixed (partly
sphere, partly adherent) morphological shapes. Speciﬁc markers
of different phases of pancreatic development (PDX-1, Isl-1 and
CK-19)wereselectedinordertofollowthedifferentiationproﬁle
of PANC-1 spheres in differentiating conditions.
As shown in Figure 3, PANC-1 spheres are CK-19 (differen-
tiation marker) negative (Figure 3B) and 70% of the cells are
PDX-1 positive (Figure 3E). Exposing spheres for 11 days to dif-
ferentiating conditions (DM) results in attachment of the spheres
to the slide increased CK-19 positivity (35% positive cells; Fig-
ure 3D). Adherent PANC-1 cells show high CK19 positivity.
Figure 3(A) shows the quantitative analysis of the percentage
of PDX-1, Isl-1 and CK-19 positivity in spheres, differentiated
spheres (cells in DM for 11 days) and adherent cells. As depic-
ted in the graph, the increased expression of the differentiation
marker CK-19 coincides with a decreased expression of the early
progenitor marker PDX-1 and the β-cell precursor marker Isl-1
in spheres exposed to DM.
PANC-1 spheres demonstrate increased
aggressiveness
Aggressiveness marker expression
It has been demonstrated that there is a clear correlation between
an increased metastatic potential of pancreas cancer and an in-
creased expression of CXCR4 [8] and OPN [9]. Since OPN was
described to be a direct downstream target gene of the human
hedgehog signalling pathway [15], the gene expression analysis
ofPANC-1spheresversusadherentlygrowingcellswasextended
toindicatorgenesoftheactivehedgehogsignallingpathway(e.g.
Shh, Gli-1 and Ptch). Hedgehog pathway activation was assessed
both at the receptor level (Shh) and at the intracellular ‘target
gene’ level (Gli-1 and Ptch).
The overexpression of the reported ‘aggressiveness’ markers
CXCR4andOPNinspheresincomparisonwithadherentPANC-
1 was conﬁrmed. Spheres showed the earlier described 350-fold
(+ −30, P<0.01) and 9.24-fold (+ −0.52, P<0.01) higher mRNA
expression of OPN and CXCR4 respectively.
Moreover, the increased OPN levels were clearly in line
with an increased hedgehog pathway activity as indicated by its
markers: spheres demonstrated a 2 (+ −0.2, P<0.05), 5 (+ −0.42,
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Figure 3 Differentiation marker analysis of differentiated PANC-1 spheres and adherent cells
(A) Analysis of PANC-1 spheres compared with differentiated (diff) spheres and adherent cells. The percentage of CK-19-,
PDX-1- and Isl-1-positive PANC-1 cells is represented as the fraction of the total number of cells. One-way ANOVA followed by
the Tukey–Kramer test for multiple comparisons was performed. CK-19 and Isl1 expression levels were signiﬁcantly different
between all three cell types (P<0.05). Expression of PDX-1 was signiﬁcantly different only between spheres and adherent
cells. (B) PANC-1 parafﬁn-embedded spheres were stained for CK-19; scale bar, 1 μm. (C) CK-19 staining of PANC-1
adherent cells in chamber slides; scale bar, 5 μm. (D) CK-19 differentiation experiments with PANC-1 sphere-growing cells
in DM for 11 days; scale bar, 1 μm. (E) Representative image of PDX-1 immunostaining of PANC-1 spheres; scale bar,
10 μm.
P<0.01) and 3.27 (+ −0.47, P<0.01) fold increase in Shh, Gli-1
and Ptch expression respectively. All differences were statistic-
ally signiﬁcant, suggesting that sphere-growing cells show in-
creases in aggressiveness markers and possess a more active
hedgehog signalling pathway.
Increased CXCR4 expression in PANC-1 spheres
regulates migration
Before investigating the potential functional role of increased
CXCR4 expression in spheres as compared with adherent cells,
the increased expression of CXCR4at the plasma membrane was
conﬁrmed. FACS analysis demonstrated that PANC-1 spheres
(19.4%) displayed an increased membrane protein expression of
CXCR4 when compared with their adherent counterparts (6.4%;
Figures 4A and 4B).
Potential association of increased membrane CXCR4 with in-
creased migration was appraised in a transwell migration as-
say. Although FBS, CSM and HGF in the lower chamber did
not result in a different migration pattern of spheres and ad-
herent cells, the addition of the natural ligand of CXCR4 as
chemoattractant (SDF-1) had a signiﬁcant effect on the mi-
gration capacity of spheres (160% of control) and not on the
adherent cells. Thus these results not only validate the func-
tional activity of CXCR4 in spheres but also conﬁrm the in-
creased migratory capacity of spheres versus adherent cells
(Figure 4C).
Pancreatic cancer spheres show a different morphology
after in vivo passage with respect to their adherent
counterpart
The morphology of tumours derived from PANC-1 spheres and
adherent cells was investigated in a xenograft mouse model.
Typically, 2×106 cells of each cell type were injected subcu-
taneously in athymic female mice. After 35 days, mice were
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Figure 4 CXCR4 surface expression in PANC-1 adherent cells and spheres
CXCR4 cell surface expression in PANC-1 adherently growing cells (A; 6.4%) and spheres (B; 19.4%) using FACS analysis.
All results are expressed as means of three independent experiments. (C) Transwell migration assay of PANC-1 spheres
compared with adherently growing cells. Average percentage of cells (normalized to DMEM serum-free medium as the
control) that migrated after 48 h from the upper to the lower chamber is shown. The medium in the lower chamber
contained the following chemoattractants: DMEM serum-free medium (as the control, ctrl); complete CSM (CSC); HGF at
200 ng/ml; DMEM serum-free medium supplemented with SDF-1 (200 ng/ml; SDF) and DMEM supplemented with 10%
FBS (10% FBS). Statistically signiﬁcant (Student’s t test; *P<0.05) differences were observed between ctrl and SDF.
killed and tumours were dissected from skin, formalin-ﬁxed
and embedded in parafﬁn. H/E staining (Figures 5A and 5B)
demonstrated that sphere-growing tumours established in nude
mice showed more irregular cells undergoing mitosis than ad-
herent cell-derived tumours. Moreover, adherent cells demon-
strated a more organized architecture, whereas the spheres
generated a more dysplastic tumour structure. Spheres were
less organized, contained more apoptotic bodies and more
cells undergoing mitosis as assessed by Ki67 immunostain-
ing on parafﬁn-embedded tumour sections. In fact, Ki67 is a
marker used to determine the growth fraction of a given cell
population [16] and showed that sphere-derived tumours had a
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Figure 5 Histological and histochemical features of PANC-1 xenograft tumours
H/E and Ki67 immunohistohemical stainings: comparison in tumours generated from PANC-1 adherently growing cells
shown in (A) (scale bar, 10 μM) and (C) (scale bar, 20 μM) and from PANC-1 spheres shown in (B) (scale bar, 10 μM) and
(D) (scale bar, 20 μM). H/E in (A, B) clearly shows that sphere cells generate a tumour proﬁle that is more aggressive
when compared with the proﬁle generated from adherently growing cells (more irregular mitotic signature, arrows). In (C,
D), Ki67 (a cellular marker strictly associated with cell proliferation)-positive nuclei are visualized in adherent cells (40%
positive nuclei) and in spheres (70–80% positive nuclei).
signiﬁcantly higher proliferation rate (70–80% positivity) when
compared with adherent cell-derived tumours (40% positivity)
(Figures 5C and 5D).
Tumour growth proﬁle from adherent cells and spheres
in the orthotopic mouse model
Ten nude mice were used to obtain orthotopic tumours from
5×105 PANC-1 cells: ﬁve were injected with sphere-growing
cells and ﬁve with adherent cells. Tumour growth was followed
using MRI for 3 months, setting the ﬁrst control at 20 days after
surgery.
Mice injected with PANC-1 sphere-growing cells developed
tumours faster than mice injected with PANC-1 adherent cells.
Inanimalsreceivingsphere-growingPANC-1cells,smallmasses
weredetectedbyMRI6 weeksaftersurgery,whereasnotumours
were seen at the same time point for the adherent-cell group. The
latter only developed detectable tumours after two additional
weeks.
Putative metastases were found in 5/5 animals injected with
sphere-growing cells, as small masses were found on the surface
of the small intestine and in the liver (Figures 6A and 6B).
Taken together, our results suggest that PANC-1 spheres (due
totheirincreasedaggressiveness)mightbeamorereliablemodel
system for studies of pancreatic cancer.
DISCUSSION
Based on a large number of studies, it has become increasingly
clear that many tumours contain a very small subpopulation of
cancer stem-like cells that are characterized by a series of highly
speciﬁc features. These cells, usually recognized by virtue of
their membrane protein expression proﬁle, exhibit typical stem
cellcharacteristicsandwerehypothesizedtobethemoreaggress-
ively growing and chemoresistant cell population of a tumour
[17–22]. Recently, some confusion has emerged in the ‘cancer
stem cell ﬁeld’ based on conﬂicting results obtained by differ-
ent researchers. For instance, it was demonstrated that stem-cell
marker-negative cells were also able to grow as spheres and to
give rise to very aggressively growing tumours in vivo.I na d d i -
tion, from a chemosensitivity study conducted on glioma cells by
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Figure 6 Putative metastasis (black arrows), derived from
sphere-growing cells, were found in the small intestine (A) and
liver (B)
Liu et al. [23], it became clear that the marker-positive cells were
not substantially more chemoresistant when compared with the
marker-negative cells. In fact, CD133-positive cells were only
15–20% more chemoresistant than CD133-negative cells upon
standard care treatment (temozolomide, carboplatin, taxol and
VP16). The aim of the present study was to enrich and char-
acterize the subpopulation of tumour cells that can mimic the
high aggressiveness of pancreas tumours observed in patients
in terms of proliferation and metastatic capacity. We capital-
ized on previous observations in other solid tumours that have
clearly demonstrated that cancer stem-like cells have the ability
to grow as spheres and do mirror the genotype and phenotype
of patient-derived tumours [24]. The opposite, showing that all
sphere-growingcellsneedtobeandareonlystem-like,hasnotyet
been investigated. Thus, instead of separating stemness marker-
positivefromnegativecells,westudiedthebehaviourandmarker
expression pattern of pancreatic tumour spheres. The main ques-
tion we wanted to answer was whether sphere-growing cells are
homogeneous ‘aggregates’ of stem-like cells only. A panel of
well-established pancreatic cancer cell lines was thus subjected
to culture conditions that have previously been demonstrated to
promote sphere forming cells (i.e. serum-free medium supple-
mented with growth factors present in the pancreatic microenvir-
onment [25]). Interestingly, we found that only some pancreatic
cancer cell lines had the capacity to form spheres under these
conditions. In fact, PancTu-1 did not form spheres even after
a long time of culture in the stem-cell-promoting medium. At
ﬁrst, this seemed contradictory to results published by Olempska
et al. [14], who reported that PancTu-1 showed high expression
levels of the typical stemness marker CD133. Besides the fact
that in our hands the CD133 levels in PancTu-1 cells were rel-
atively low, a multiparametric analysis (PCA) using expression
values of all pancreatic cancer stem-associated markers [7] was
unable to differentiate the lines that show a sphere-growing capa-
city from those that do not. Only when mRNA expression values
from markers that in previous studies were reported to be asso-
ciated with the aggressive/highly metastatic behaviour of pan-
creatic cancer [9,26–29] (such as CXCR4, OPN and CD44v6)
were included, the two cell populations could be successfully
separated by PCA. To our knowledge, these results point, for the
ﬁrst time, in the direction that (although spheres demonstrate the
typicalcharacteristicsofstem-likecells,suchasself-renewaland
multidifferentiation) spheres potentially display something more
than stem cell characteristics alone. Therefore, in a subsequent
phase of our present study, we investigated functional features
of pancreatic cancer sphere-growing cells. Our results demon-
strated that the pancreatic cancer spheres were not only more
invasive in vitro but also demonstrated a more aggressive prolif-
eration,invasionandmetastasiscapacityinvivo.Thusthesefunc-
tional studies conﬁrmed our initial observation based on marker
analysis employing PCA. Taken together, our present study has
demonstrated that the pancreatic cancer spheres are more than
just cancer stem-like cells. In addition, as these sphere-growing
cells can be maintained relatively easily we have also generated
a cell line-derived pancreatic cancer model that demonstrates the
characteristics of the clinically relevant tumour. This cell system
might be very useful to further the understanding of certain as-
pects of pancreatic cancer and could also be employed to screen
compounds for therapeutic intervention.
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